Critical care management of patients with end-stage liver disease

Critical Care Medicine

Volumn 39, Issue 5, 2011, Pages 1157-1166

  Al Khafaji, Ali ^a,b   Huang, David T ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

decompensated cirrhosis; encephalopathy; end stage liver disease; hepatopulmonary syndrome; hepatorenal syndrome; portopulmonary hypertension; portosystemic encephalopathy; variceal bleeding

Indexed keywords

ACARBOSE; ACETYLCYSTEINE; ALBUMIN; ANTIBIOTIC AGENT; BENZOIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; DOPAMINE; HETASTARCH; ILOPROST; LACTULOSE; METRONIDAZOLE; MIDODRINE; NEOMYCIN; NITRATE; NITRIC OXIDE; NORADRENALIN; OCTREOTIDE; ORNITHINE ASPARTATE; PROSTACYCLIN; RIFAXIMIN; SILDENAFIL; TERLIPRESSIN; UNINDEXED DRUG; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VASOPRESSIN; VITAMIN K GROUP;

ADD ON THERAPY; ADULT RESPIRATORY DISTRESS SYNDROME; ASCITES; AWARENESS; BACTERIAL PERITONITIS; BLOOD CLOTTING DISORDER; CONFERENCE PAPER; DRUG DOSE TITRATION; ESOPHAGUS VARICES BLEEDING; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HUMAN; INFECTION; INTENSIVE CARE; LIVER; LIVER DISEASE; LIVER TRANSPLANTATION; MEDICAL RECORD REVIEW; MORBIDITY; MORTALITY; NONHUMAN; ORGAN; OXYGEN THERAPY; PARACENTESIS; PHYSICIAN; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; STUDY DESIGN; TACHYCARDIA;

EID: 79955480185     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318211fdc4     Document Type: Conference Paper

References (188)

1. Aggarwal A, Ong JP, Younossi ZM, et al: Predictors of mortality and resource utili-zation in cirrhotic patients admitted to the medical ICU. Chest 2001; 119:1489-1497 (Pubitemid 32686034)
2. Kress JP, Rubin A, Pohlman AS, et al: Out-comes of critically ill patients denied con-sideration for liver transplantation. Am J Respir Crit Care Med 2000; 162(2 Pt 1): 418-423 (Pubitemid 30647176)
3. Singh N, Gayowski T, Wagener MM, et al: Outcome of patients with cirrhosis requir-ing intensive care unit support: prospective assessment of predictors of mortality. J Gastroenterol 1998; 33:73-79 (Pubitemid 28067778)
4. Moreau R, Hadengue A, Soupison T, et al: Septic shock in patients with cirrhosis: He-modynamic and metabolic characteristics and intensive care unit outcome. Crit Care Med 1992; 20:746-750
5. Das V, Boelle PY, Galbois A, et al: Cirrhotic patients in the medical intensive care unit: Early prognosis and long-term survival. Crit Care Med 2010; 38:2108-2116
6. Murray KF, Carithers RL Jr: AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-1432 (Pubitemid 40770295)
7. Uribe M, Campollo O, Vargas F, et al: Acid-ifying enemas (lactitol and lactose) vs. non-acidifying enemas (tap water) to treat acute portal-systemic encephalopathy: A double-blind, randomized clinical trial. Hepatology 1987; 7:639-643 (Pubitemid 17130704)
8. Mortensen PB: The effect of oral-adminis-tered lactulose on colonic nitrogen metab-olism and excretion. Hepatology 1992; 16: 1350-1356
9. Riggio O, Varriale M, Testore GP, et al: Effect of lactitol and lactulose administra-tion on the fecal flora in cirrhotic patients. J Clin Gastroenterol 1990; 12:433-436 (Pubitemid 20234375)
10. Als-Nielsen B, Gluud LL, Gluud C: Non-absorbable disaccharides for hepatic en-cephalopathy: Systematic review of ran-domised trials. BMJ 2004; 328:1046
11. Prasad S, Dhiman RK, Duseja A, et al: Lac-tulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic en-cephalopathy. Hepatology 2007; 45: 549-559 (Pubitemid 46450607)
12. Sharma BC, Sharma P, Agrawal A, et al: Secondary prophylaxis of hepatic encepha-lopathy: An open-label randomized con-trolled trial of lactulose versus placebo. Gastroenterology 2009; 137:885-891, e881
13. Bucci L, Palmieri GC: Double-blind, dou-ble-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic en-cephalopathy. Curr Med Res Opin 1993; 13: 109-118 (Pubitemid 23187314)
14. Venturini I, Ferrieri A, Farina F, et al: Eval-uation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: A pilot study. Drugs Exp Clin Res 2005; 31:161-168 (Pubitemid 41415171)
15. Jiang Q, Jiang XH, Zheng MH, et al: Rifaxi-min versus nonabsorbable disaccharides in the management of hepatic encephalopa-thy: A meta-analysis. Eur J Gastroenterol Hepatol 2008; 20:1064-1070
16. Bass NM, Mullen KD, Sanyal A, et al: Rifaxi-min treatment in hepatic encephalopathy. N Engl J Med 2010; 362:1071-1081
17. Cordoba J, Lopez-Hellin J, Planas M, et al: Normal protein diet for episodic hepatic en-cephalopathy: results of a randomized study. J Hepatol 2004; 41:38-43 (Pubitemid 39005150)
18. Macbeth WA, Kass EH, McDermott WV Jr: Treatment of hepatic encephalopathy by al-teration of intestinal flora with lactobacillus acidophilus. Lancet 1965; 1:399-403
19. Bajaj JS, Saeian K, Christensen KM, et al: Probiotic yogurt for the treatment of min-imal hepatic encephalopathy. Am J Gastro-enterol 2008; 103:1707-1715
20. Gentile S, Guarino G, Romano M, et al: A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005; 3:184-191 (Pubitemid 40220314)
21. Kircheis G, Nilius R, Held C, et al: Thera-peutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled, double-blind study. Hepatology 1997; 25:1351-1360 (Pubitemid 27250753)
22. Staedt U, Leweling H, Gladisch R, et al: Effects of ornithine aspartate on plasma ammonia and plasma amino acids in pa-tients with cirrhosis. A double-blind, ran-domized study using a four-fold crossover design. JHepatol 1993; 19:424-430 (Pubitemid 24029921)
23. Stauch S, Kircheis G, Adler G, et al: Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a place-bo-controlled double-blind study.JHepatol 1998; 28:856-864 (Pubitemid 28223491)
24. Sushma S, Dasarathy S, Tandon RK, et al: Sodium benzoate in the treatment of acute hepatic encephalopathy: A double-blind randomized trial. Hepatology 1992; 16: 138-144
25. Hassanein TI, Tofteng F, Brown RS Jr, et al: Randomized controlled study of extracorpo-real albumin dialysis for hepatic encepha-lopathy in advanced cirrhosis. Hepatology 2007; 46:1853-1862
26. Mitzner SR, Stange J, Klammt S, et al: Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, con-trolled clinical trial. Liver Transpl 2000; 6:277-286 (Pubitemid 30317221)
27. Mitzner SR, Klammt S, Peszynski P, et al: Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recir-culating system. Ther Apher 2001; 5:417-422 (Pubitemid 34033340)
28. Hollenberg SM: Recognition and treatment of cardiogenic shock. Semin Respir Crit Care Med 2004; 25:661-671 (Pubitemid 40041586)
29. Hollenberg SM, Ahrens TS, Annane D, et al: Practice parameters for hemodynamic sup-port of sepsis in adult patients: 2004 update. Crit Care Med 2004; 32:1928-1948 (Pubitemid 39202372)
30. Groszmann RJ: Hyperdynamic circulation of liver disease 40 years later: pathophysiol-ogy and clinical consequences. Hepatology 1994; 20:1359-1363 (Pubitemid 24323589)
31. Kowalski HJ, Abelmann WH: The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32:1025-1033
32. Al-Hamoudi WK: Cardiovascular changes in cirrhosis: Pathogenesis and clinical impli-cations. Saudi J Gastroenterol 2010; 16: 145-153
33. Moller S, Henriksen JH: Cardiovascular complications of cirrhosis. Gut 2008; 57: 268-278 (Pubitemid 351158057)
34. Wong F: Cirrhotic cardiomyopathy. Hepatol Int 2009; 3:294-304
35. Zardi EM, Abbate A, Zardi DM, et al: Cir-rhotic cardiomyopathy. J Am Coll Cardiol 2010; 56:539-549
36. Duchini A, Viernes ME, Nyberg LM, et al: Hepatic decompensation in patients with cirrhosis during infection with influenza A. Arch Intern Med 2000; 160:113-115 (Pubitemid 30040980)
37. Ruiz-del-Arbol L, Urman J, Fernandez J, et al: Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38:1210-1218 (Pubitemid 37314829)
38. Umgelter A, Reindl W, Geisler F, et al: Ef-fects of TIPS on global end-diastolic volume and cardiac output and renal resistive index in ICU patients with advanced alcoholic cir-rhosis. Ann Hepatol 2010; 9:40-45
39. Sola-Vera J, Such J: Understanding the mechanisms of paracentesis-induced circu-latory dysfunction. Eur J Gastroenterol Hepatol 2004; 16:295-298 (Pubitemid 38368373)
40. Wong F, Girgrah N, Graba J, et al: The cardiac response to exercise in cirrhosis. Gut 2001; 49:268-275 (Pubitemid 32675122)
41. Laffi G, Barletta G, La Villa G, et al: Altered cardiovascular responsiveness to active tilt-ing in nonalcoholic cirrhosis. Gastroenter-ology 1997; 113:891-898 (Pubitemid 27381149)
42. Bolognesi M, Sacerdoti D, Di Pascoli M, et al: Haeme oxygenase mediates hyporeactiv-ity to phenylephrine in the mesenteric ves-sels of cirrhotic rats with ascites. Gut 2005; 54:1630-1636 (Pubitemid 41531784)
43. Kojima H, Sakurai S, Uemura M, et al: Ad-renomedullin contributes to vascular hypo-reactivity in cirrhotic rats with ascites via a release of nitric oxide. Scand J Gastroen-terol 2004; 39:686-693 (Pubitemid 38916247)
44. Marik PE, Gayowski T, Starzl TE: The hepa-toadrenal syndrome: A common yet unrec-ognized clinical condition. Crit Care Med 2005; 33:1254-1259 (Pubitemid 40827374)
45. Tayek JA: Lower cortisol concentrations in patients with liver disease: More adrenal failure or more confusion? Crit Care Med 2005; 33:1431-1432 (Pubitemid 40827406)
46. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
47. Almenoff PL, Leavy J, Weil MH, et al: Pro-longation of the half-life of lactate after maximal exercise in patients with hepatic dysfunction. Crit Care Med 1989; 17: 870-873 (Pubitemid 19233314)
48. Agusti AG, Roca J, Rodriguez-Roisin R, et al: Pulmonary hemodynamics and gas ex-change during exercise in liver cirrhosis. Am Rev Respir Dis 1989; 139:485-491 (Pubitemid 19057430)
49. Berthelot P, Walker JG, Sherlock S, et al: Arterial changes in the lungs in cirrhosis of the liver-Lung spider nevi. N Engl J Med 1966; 274:291-298
50. Hoeper MM, Krowka MJ, Strassburg CP: Portopulmonary hypertension and hepa-topulmonary syndrome. Lancet 2004; 363: 1461-1468
51. Kennedy TC, Knudson RJ: Exercise-aggra-vated hypoxemia and orthodeoxia in cirrho-sis. Chest 1977; 72:305-309
52. Schenk P, Fuhrmann V, Madl C, et al: Hepa-topulmonary syndrome: prevalence and predictive value of various cut offs for arte-rial oxygenation and their clinical conse-quences. Gut 2002; 51:853-859 (Pubitemid 35408608)
53. Fallon MB, Abrams GA, Luo B, et al: The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepa-topulmonary syndrome. Gastroenterology 1997; 113:606-614 (Pubitemid 27351790)
54. Rodriguez-Roisin R, Krowka MJ: Hepa-topulmonary syndrome-A liver-induced lung vascular disorder. N Engl J Med 2008; 358:2378-2387
55. De BK, Sen S, Biswas PK, et al: Occurrence of hepatopulmonary syndrome in Budd-Chiari syndrome and the role of venous decompression. Gastroenterology 2002; 122:897-903 (Pubitemid 34267272)
56. Swanson KL, Wiesner RH, Krowka MJ: Nat-ural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005; 41:1122-1129 (Pubitemid 40593920)
57. Schwarzenberg SJ, Freese DK, Regelmann WE, et al: Resolution of severe intrapulmo-nary shunting after liver transplantation. Chest 1993; 103:1271-1273 (Pubitemid 23110315)
58. Hadengue A, Benhayoun MK, Lebrec D, et al: Pulmonary hypertension complicating portal hypertension: Prevalence and rela-tion to splanchnic hemodynamics. Gastro-enterology 1991; 100:520-528
59. McDonnell PJ, Toye PA, Hutchins GM: Pri-mary pulmonary hypertension and cirrho-sis: Are they related? Am Rev Respir Dis 1983; 127:437-441 (Pubitemid 13083742)
60. Rodriguez-Roisin R, Krowka MJ, Herve P, et al: Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004; 24:861-880 (Pubitemid 39504442)
61. Benjaminov FS, Prentice M, Sniderman KW, et al: Portopulmonary hypertension in decompensated cirrhosis with refractory as-cites. Gut 2003; 52:1355-1362 (Pubitemid 37026471)
62. Castro M, Krowka MJ, Schroeder DR, et al: Frequency and clinical implications of in-creased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996; 71:543-551
63. Colle IO, Moreau R, Godinho E, et al: Diag-nosis of portopulmonary hypertension in candidates for liver transplantation: A pro-spective study. Hepatology 2003; 37: 401-409 (Pubitemid 36152540)
64. Plevak D, Krowka M, Rettke S, et al: Suc-cessful liver transplantation in patients with mild to moderate pulmonary hypertension. Transplant Proc 1993; 25:1840 (Pubitemid 23125110)
65. Ramsay MA, Simpson BR, Nguyen AT, et al: Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997; 3:494-500 (Pubitemid 27427898)
66. Taura P, Garcia-Valdecasas JC, Beltran J, et al: Moderate primary pulmonary hyperten-sion in patients undergoing liver transplan-tation. Anesth Analg 1996; 83:675-680 (Pubitemid 26349197)
67. Lebrec D, Capron JP, Dhumeaux D, et al: Pulmonary hypertension complicating por-tal hypertension. Am Rev Respir Dis 1979; 120:849-856
68. Maruyama T, Ohsaki K, Shimoda S, et al: Thromboxane-dependent portopulmonary hypertension. Am J Med 2005; 118:93-94
69. Krowka MJ, Mandell MS, Ramsay MA, et al: Hepatopulmonary syndrome and portopulmonary hypertension: A report of the mul-ticenter liver transplant database. Liver Transpl 2004; 10:174-182 (Pubitemid 38240114)
70. Swanson KL, Wiesner RH, Nyberg SL, et al: Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 8:2445-2453
71. Friedman R, Mears JG, Barst RJ: Continu-ous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmo-nary hypertension. Circulation 1997; 96: 2782-2784 (Pubitemid 27500070)
72. Rubin LJ: Primary pulmonary hyperten-sion. N Engl J Med 1997; 336:111-117
73. Barst RJ, Rubin LJ, Long WA, et al: A com-parison of continuous intravenous epopro-stenol (prostacyclin) with conventional therapy for primary pulmonary hyperten-sion. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302
74. Barst RJ, Rubin LJ, McGoon MD, et al: Sur-vival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409-415
75. Kett DH, Acosta RC, Campos MA, et al: Recurrent portopulmonary hypertension af-ter liver transplantation: Management with epoprostenol and resolution after retrans-plantation. Liver Transpl 2001; 7:645-648 (Pubitemid 32677891)
76. Plotkin JS, Kuo PC, Rubin LJ, et al: Suc-cessful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplan-tation 1998; 65:457-459 (Pubitemid 28136484)
77. Rubin LJ, Mendoza J, Hood M, et al: Treat-ment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112:485-491 (Pubitemid 20100285)
78. Shapiro SM, Oudiz RJ, Cao T, et al: Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30:343-349 (Pubitemid 27339311)
79. Tan HP, Markowitz JS, Montgomery RA, et al: Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intrave-nous epoprostenol. Liver Transpl 2001; 7:745-749 (Pubitemid 32771477)
80. Grander W, Eller P, Fuschelberger R, et al: Bosentan treatment of portopulmonary hy-pertension related to liver cirrhosis owing to hepatitis C. Eur J Clin Invest 2006; 36(Suppl 3):67-70 (Pubitemid 44179785)
81. Hinterhuber L, Graziadei IW, Kahler CM, et al: Endothelin-receptor antagonist treat-ment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2004; 2:1039-1042 (Pubitemid 39539755)
82. Hoeper MM, Halank M, Marx C, et al: Bosentan therapy for portopulmonary hy-pertension. Eur Respir J Mar 2005; 25: 502-508
83. Hoeper MM, Seyfarth HJ, Hoeffken G, et al: Experience with inhaled iloprost and bosen-tan in portopulmonary hypertension. Eur Respir J Dec 2007; 30:1096-1102 (Pubitemid 351194755)
84. Kuntzen C, Gulberg V, Gerbes AL: Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: A safe and effective therapy? Gastroenterology 2005; 128:164-168 (Pubitemid 40039967)
85. Neuhofer W, Gulberg V, Gerbes AL: Endo-thelin and endothelin receptor antagonism in portopulmonary hypertension. EurJ Clin Invest 2006; 36(Suppl 3):54-61 (Pubitemid 44179783)
86. Chua R, Keogh A, Miyashita M: Novel use of sildenafil in the treatment of portopulmo-nary hypertension. J Heart Lung Trans-plant 2005; 24:498-500 (Pubitemid 40403811)
87. Reichenberger F, Voswinckel R, Steveling E, et al: Sildenafil treatment for portopul-monary hypertension. Eur Respir J Sep 2006; 28:563-567
88. Halank M, Marx C, Miehlke S, et al: Use of aerosolized inhaled iloprost in the treat-ment of portopulmonary hypertension. J Gastroenterol 2004; 39:1222-1223 (Pubitemid 40074294)
89. Minder S, Fischler M, Muellhaupt B, et al: Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hy-pertension. Eur Respir J 2004; 24:703-707 (Pubitemid 39406146)
90. Koneru B, Ahmed S, Weisse AB, et al: Res-olution of pulmonary hypertension of cir-rhosis after liver transplantation. Trans-plantation 1994; 58:1133-1135 (Pubitemid 24377934)
91. Schott R, Chaouat A, Launoy A, et al: Im-provement of pulmonary hypertension after liver transplantation. Chest 1999; 115: 1748-1749 (Pubitemid 29275676)
92. Krowka MJ, Plevak DJ, Findlay JY, et al: Pulmonary hemodynamics and periopera-tive cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6:443-450 (Pubitemid 30489117)
93. TenHoor T, Mannino DM, Moss M: Risk factors for ARDS in the United States: Anal-ysis of the 1993 National Mortality Follow-back Study. Chest 2001; 119:1179-1184 (Pubitemid 32679448)
94. Tilg H, Wilmer A, Vogel W, et al: Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103:264-274
95. Diaz JV, Brower R, Calfee CS, et al: Thera-peutic strategies for severe acute lung in-jury. Crit Care Med 2010; 38:1644-1650
96. The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal vol-umes as compared with traditional tidal vol-umes for acute lung injury and the acute respiratory distress syndrome. NEnglJMed 2000; 342:1301-1308
97. Gines A, Fernandez-Esparrach G, Monescillo A, et al: Randomized trial comparing albumin, dextran 70, and polygeline in cir-rhotic patients with ascites treated by para-centesis. Gastroenterology 1996; 111: 1002-1010 (Pubitemid 26327603)
98. Gines P, Tito L, Arroyo V, et al: Randomized comparative study of therapeutic paracen-tesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-1502
99. Salo J, Gines A, Gines P, et al: Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. J Hepatol 1997; 27: 645-653 (Pubitemid 27448748)
100. Huang PM, Chang YL, Yang CY, et al: The morphology of diaphragmatic defects in he-patic hydrothorax: thoracoscopic finding. J Thorac Cardiovasc Surg 2005; 130: 141-145
101. Albillos A, Banares R, Gonzalez M, et al: A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 2005; 43: 990-996 (Pubitemid 41627984)
102. DAmico G, Luca A, Morabito A, et al: Un-covered transjugular intrahepatic portosys-temic shunt for refractory ascites: A meta-analysis. Gastroenterology 2005; 129: 1282-1293 (Pubitemid 41446867)
103. Deltenre P, Mathurin P, Dharancy S, et al: Transjugular intrahepatic portosystemic shunt in refractory ascites: A meta-analysis. Liver Int 2005; 25:349-356
104. Saab S, Nieto JM, Lewis SK, et al: TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2006;(4):CD004889
105. Saab S, Nieto JM, Ly D, et al: TIPS versus paracentesis for cirrhotic patients with re-fractory ascites. Cochrane Database Syst Rev 2004;(3):CD004889
106. Salerno F, Camma C, Enea M, et al: Tran-sjugular intrahepatic portosystemic shunt for refractory ascites: A meta-analysis of in-dividual patient data. Gastroenterology 2007; 133:825-834 (Pubitemid 47374134)
107. Huang PM, Kuo SW, Lee JM: Thoracoscopic diaphragmatic repair for refractory hepatic hydrothorax: Application of pleural flap and mesh onlay reinforcement. Thorac Cardio-vasc Surg 2006; 54:47-50
108. Gines P, Arroyo V, Vargas V, et al: Paracen-tesis with intravenous infusion of albumin as compared with peritoneovenous shunt-ing in cirrhosis with refractory ascites. N Engl J Med 1991; 325:829-835
109. Stanley MM, Ochi S, Lee KK, et al: Perito-neovenous shunting as compared with medical treatment in patients with alco-holic cirrhosis and massive ascites. Veter-ans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with As-cites. N Engl J Med 1989; 321:1632-1638 (Pubitemid 20012914)
110. Abrams GA, Sanders MK, Fallon MB: Utility of pulse oximetry in the detection of arterial hypoxemia in liver transplant candidates. Liver Transpl 2002; 8:391-396 (Pubitemid 34467375)
111. Lampert R, Brandt L: [The effect of hyper-bilirubinemia on the measurement of oxy-genated hemoglobin (O2Hb), carboxyhemo-globin (COHb) and methemoglobin (MetHb) using multiwavelength oximeters in mixed venous blood.] Anaesthesist 1993; 42:702-709
112. Veyckemans F, Baele P, Guillaume JE, et al: Hyperbilirubinemia does not interfere with hemoglobin saturation measured by pulse oximetry. Anesthesiology 1989; 70:118-122 (Pubitemid 19042774)
113. Carbonell N, Pauwels A, Serfaty L, et al: Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004; 40:652-659 (Pubitemid 39265587)
114. Garcia-Tsao G, Bosch J: Managementofvarices and variceal hemorrhage in cirrhosis. NEngl J Med 2010; 362:823-832
115. Garcia-Tsao G, Sanyal AJ, Grace ND, et al: Prevention and management of gastro-esophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46:922-938 (Pubitemid 47436138)
116. Corley DA, Cello JP, Adkisson W, et al: Oc-treotide for acute esophageal variceal bleed-ing: A meta-analysis. Gastroenterology 2001; 120:946-954 (Pubitemid 32193191)
117. DAmico G, Pagliaro L, Bosch J: Pharmaco-logical treatment of portal hypertension: An evidence-based approach. Semin Liver Dis 1999; 19:475-505 (Pubitemid 30032646)
118. DAmico G, Pietrosi G, Tarantino I, et al: Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: A Cochrane meta-analysis. Gastroenterology 2003; 124:1277-1291 (Pubitemid 36531803)
119. Gotzsche PC, Hrobjartsson A: Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database Syst Rev 2008; (3):CD000193
120. Groszmann RJ, Kravetz D, Bosch J, et al: Nitroglycerin improves the hemodynamic response to vasopressin in portal hyperten-sion. Hepatology 1982; 2:757-762 (Pubitemid 13204363)
121. Bernard B, Grange JD, Khac EN, et al: An-tibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta-analysis. Hepatology 1999; 29:1655-1661 (Pubitemid 29247035)
122. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al: Antibiotic prophylaxis for cirrhotic patients with upper gastroin-testinal bleeding. Cochrane Database Syst Rev 2010; (9):CD002907
123. Fernandez J, Ruiz del Arbol L, Gomez C, et al: Norfloxacin vs ceftriaxone in the prophy-laxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterol-ogy 2006; 131:1049-1056, quiz 1285 (Pubitemid 44498687)
124. Hou MC, Lin HC, Liu TT, et al: Antibiotic prophylaxis after endoscopic therapy pre-vents rebleeding in acute variceal hemor-rhage: A randomized trial. Hepatology 2004; 39:746-753
125. Rimola A, Garcia-Tsao G, Navasa M, et al: Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: A consen-sus document. International Ascites Club. J Hepatol 2000; 32:142-153 (Pubitemid 30039459)
126. de Franchis R, Primignani M: Endoscopic treatments for portal hypertension. Semin LiverDis 1999; 19:439-455 (Pubitemid 30032644)
127. Garcia-Pagan JC, Bosch J: Endoscopicband ligation in the treatment of portal hyper-tension. Nat Clin Pract Gastroenterol Hepatol 2005; 2:526-535 (Pubitemid 43135271)
128. Laine L, Cook D: Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995; 123: 280-287
129. Banares R, Albillos A, Rincon D, et al: En-doscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: A meta-analysis. Hepatology 2002; 35:609-615 (Pubitemid 34183965)
130. Lo GH, Lai KH, Cheng JS, et al: A prospec-tive, randomized trial of butyl cyanoacrylate injection versus band ligation in the man-agement of bleeding gastric varices. Hepa-tology 2001; 33:1060-1064
131. Tan PC, Hou MC, Lin HC, et al: A random-ized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band liga-tion. Hepatology 2006; 43:690-697
132. Chau TN, Patch D, Chan YW, et al: "Sal-vage" transjugular intrahepatic portosys-temic shunts: Gastric fundal compared with esophageal variceal bleeding. Gastroenter-ology 1998; 114:981-987 (Pubitemid 28217564)
133. Boyer TD, Haskal ZJ: The role of transjugu-lar intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: Update 2009. Hepatology 2010; 51:306
134. Garcia-Pagan JC, Caca K, Bureau C, et al: Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362:2370-2379
135. Angermayr B, Cejna M, Koenig F, et al: Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology 2003; 38:1043-1050 (Pubitemid 37221688)
136. Bureau C, Garcia-Pagan JC, Otal P, et al: Improved clinical outcome using polytetra-fluoroethylene-coated stents for TIPS: re-sults of a randomized study. Gastroenterol-ogy 2004; 126:469-475 (Pubitemid 38182304)
137. Henderson JM, Boyer TD, Kutner MH, et al: Distal splenorenal shunt versus transjugu-lar intrahepatic portal systematic shunt for variceal bleeding: A randomized trial. Gas-troenterology 2006; 130:1643-1651 (Pubitemid 43668831)
138. Arroyo V, Gines P, Gerbes AL, et al: Defini-tion and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrho-sis. International Ascites Club. Hepatology 1996; 23:164-176 (Pubitemid 26012105)
139. Salerno F, Gerbes A, Gines P, et al: Diagno-sis, prevention and treatment of hepatore-nal syndrome in cirrhosis. Gut 2007; 56: 1310-1318 (Pubitemid 47300435)
140. Gines P, Schrier RW: Renal failure in cir-rhosis. N Engl J Med 2009; 361:1279-1290
141. Kamath PS, Wiesner RH, Malinchoc M, et al: A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464-470 (Pubitemid 32119037)
142. Alessandria C, Ozdogan O, Guevara M, et al: MELD score and clinical type predict prog-nosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41: 1282-1289 (Pubitemid 40770280)
143. Cazzaniga M, Dionigi E, Gobbo G, et al: The systemic inflammatory response syndrome in cirrhotic patients: Relationship with their in-hospital outcome. J Hepatol 2009; 51:475-482
144. Martin-Llahi M, Pepin MN, Guevara M, et al: Terlipressin and albumin vs albumin in pa-tients with cirrhosis and hepatorenal syn-drome: A randomized study. Gastroenterol-ogy 2008; 134:1352-1359 (Pubitemid 351626950)
145. Fernandez J, Monteagudo J, Bargallo X, et al: A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42:627-634 (Pubitemid 41233655)
146. Sort P, Navasa M, Arroyo V, et al: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341:403-409 (Pubitemid 29362513)
147. Savino JA, Cerabona T, Agarwal N, et al: Manipulation of ascitic fluid pressure in cir-rhotics to optimize hemodynamic and renal function. Ann Surg 1988; 208:504-511 (Pubitemid 18266466)
148. Umgelter A, Reindl W, Franzen M, et al: Renal resistive index and renal function be-fore and after paracentesis in patients with hepatorenal syndrome and tense ascites. In-tensive Care Med 2009; 35:152-156
149. Umgelter A, Reindl W, Wagner KS, et al: Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic pa-tients with tense ascites and hepatorenal syndrome: A prospective uncontrolled trial. Crit Care 2008; 12:R4
150. Angeli P, Volpin R, Gerunda G, et al: Rever-sal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29:1690-1697 (Pubitemid 29247040)
151. Angeli P, Volpin R, Piovan D, et al: Acute effects of the oral administration of mido-drine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cir-rhotic patients with ascites. Hepatology 1998; 28:937-943 (Pubitemid 28450253)
152. Esrailian E, Pantangco ER, Kyulo NL, et al: Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syn-drome. Dig Dis Sci 2007; 52:742-748
153. Pomier-Layrargues G, Paquin SC, Hassoun Z, et al: Octreotide in hepatorenal syn-drome: A randomized, double-blind, place-bo-controlled, crossover study. Hepatology 2003; 38:238-243 (Pubitemid 36775816)
154. Skagen C, Einstein M, Lucey MR, et al: Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepato-renal syndrome. J Clin Gastroenterol 2009; 43:680-685
155. Tandon P, Tsuyuki RT, Mitchell L, et al: The effect of 1 month of therapy with mido-drine, octreotide-LAR and albumin in re-fractory ascites: A pilot study. Liver Int 2009; 29:169-174
156. Hadengue A, Gadano A, Moreau R, et al: Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29:565-570 (Pubitemid 28484945)
157. Moreau R, Durand F, Poynard T, et al: Ter-lipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology 2002; 122:923-930 (Pubitemid 34267275)
158. Halimi C, Bonnard P, Bernard B, et al: Ef-fect of terlipressin (Glypressin) on hepato-renal syndrome in cirrhotic patients: Results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002; 14:153-158 (Pubitemid 34163994)
159. Neri S, Pulvirenti D, Malaguarnera M, et al: Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008; 53:830-835 (Pubitemid 351317073)
160. Ortega R, Gines P, Uriz J, et al: Terlipressin therapy with and without albumin for pa-tients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology 2002; 36(4 Pt 1):941-948
161. Sanyal AJ, Boyer T, Garcia-Tsao G, et al: A randomized, prospective, double-blind, pla-cebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134:1360-1368 (Pubitemid 351615358)
162. Solanki P, Chawla A, Garg R, et al: Benefi-cial effects of terlipressin in hepatorenal syndrome: A prospective, randomized pla-cebo-controlled clinical trial. J Gastroen-terol Hepatol 2003; 18:152-156 (Pubitemid 36349860)
163. Kiser TH, Fish DN, Obritsch MD, et al: Vasopressin, not octreotide, may be benefi-cial in the treatment of hepatorenal syndrome: A retrospective study. Nephrol Dial Transplant 2005; 20:1813-1820 (Pubitemid 41222593)
164. Kiser TH, Maclaren R, Fish DN: Treatment of hepatorenal syndrome. Pharmacother-apy 2009; 29:1196-1211
165. Alessandria C, Ottobrelli A, Debernardi-Venon W, et al: Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47:499-505 (Pubitemid 47331744)
166. Sharma P, Kumar A, Shrama BC, et al: An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syn-drome and predictors of response. Am J Gastroenterol 2008; 103:1689-1697
167. Holt S, Goodier D, Marley R, et al: Improve-ment in renal function in hepatorenal syn-drome with N-acetylcysteine. Lancet 1999; 353:294-295 (Pubitemid 29088129)
168. Bennett WM, Keeffe E, Melnyk C, et al: Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 1975; 135:964-971
169. Brenard R, Moreau R, Pussard E, et al: He-modynamic and sympathetic responses to human atrial natriuretic peptide infusion in patients with cirrhosis. J Hepatol 1992; 14: 347-356
170. Gadano A, Moreau R, Vachiery F, et al: Na-triuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory as-cites. J Hepatol 1997; 26:1229-1234 (Pubitemid 27346634)
171. Gines A, Salmeron JM, Gines P, et al: Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in pa-tients with cirrhosis and ascites with hypo-natremia or renal failure. J Hepatol 1993; 17:220-226 (Pubitemid 23054491)
172. Wong F, Moore K, Dingemanse J, et al: Lack of renal improvement with nonselective en-dothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology 2008; 47:160-168 (Pubitemid 351171053)
173. Leber B, Mayrhauser U, Rybczynski M, et al: Innate immune dysfunction in acute and chronic liver disease. Wien Klin Wochen-schr 2009; 121:732-744
174. Tandon P, Garcia-Tsao G: Bacterial infec-tions, sepsis, and multiorgan failure in cir-rhosis. Semin Liver Dis 2008; 28:26-42 (Pubitemid 351326531)
175. Thalheimer U, Triantos CK, Samonakis DN, et al: Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005; 54:556-563 (Pubitemid 40395508)
176. Gustot T, Durand F, Lebrec D, et al: Severe sepsis in cirrhosis. Hepatology 2009; 50: 2022-2033
177. Wong F, Bernardi M, Balk R, et al: Sepsis in cirrhosis: Report on the 7th meeting of the International Ascites Club. Gut 2005; 54: 718-725 (Pubitemid 40559261)
178. Arvaniti V, DAmico G, Fede G, et al: Infec-tions in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139:1246-1256
179. Vazquez JA: Invasive fungal infections in the intensive care unit. Semin Respir Crit Care Med 2010; 31:79-86
180. Pappas PG, Kauffman CA, Andes D, et al: Clinical practice guidelines for the manage-ment of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-535
181. Fernandez J, Navasa M, Gomez J, et al: Bacterial infections in cirrhosis: Epidemio-logical changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35:140-148 (Pubitemid 34032554)
182. Chinnock B, Afarian H, Minnigan H, et al: Physician clinical impression does not rule out spontaneous bacterial peritonitis in pa-tients undergoing emergency department paracentesis. Ann Emerg Med 2008; 52: 268-273
183. Garcia-Tsao G: Spontaneous bacterial peri-tonitis: A historical perspective. J Hepatol 2004; 41:522-527
184. Wong CL, Holroyd-Leduc J, Thorpe KE, et al: Does this patient have bacterial perito-nitis or portal hypertension? How do I per-form a paracentesis and analyze the results? JAMA 2008; 299:1166-1178 (Pubitemid 351398431)
185. Runyon BA: Management of adult patients with ascites due to cirrhosis: An update. Hepatology 2009; 49:2087-2107
186. Gines P, Angeli P, Lenz K, et al: EASL clinical practice guidelines on the manage-ment of ascites, spontaneous bacterial peri-tonitis, and hepatorenal syndrome in cir-rhosis. J Hepatol 2010; 53:397-417
187. Gines P, Cardenas A, Arroyo V, et al: Man-agement of cirrhosis and ascites. N Engl J Med 2004; 350:1646-1654
188. Sigal SH, Stanca CM, Fernandez J, et al: Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007; 56:597-599 (Pubitemid 46580522)